US pharmaceutical giant Pfizer (NYSE: PFE) has announced a strategic partnership agreement with China’s Health China Research Center (HCRC). This long-term collaboration is aimed at supporting the “Healthy China” initiative, with a focus on several key areas including research into equitable access to basic health services, the scientific and standardized management of the medical and health security system, discussions on major health China special actions, and the realization of relevant medical and health development goals.
Focus on Equitable Access and Health Security System Management
The partnership will prioritize research into more equitable access to basic health services across China, ensuring that the population has fair access to essential healthcare. Additionally, the collaboration will focus on the scientific and standardized management of the medical and health security system, which is crucial for the effective functioning of the country’s healthcare infrastructure.
Discussions on Health China Special Actions and Development Goals
The agreement also encompasses relevant discussions on major health China special actions, which are targeted initiatives designed to improve public health outcomes. Furthermore, the partnership will work towards the realization of relevant medical and health development goals, aligning with the broader objectives of the “Healthy China” plan.
About the Health China Research Center (HCRC)
The Health China Research Center (HCRC) is a national think tank initiated by the China Population and Development Research Center in 2021. It plays a significant role in shaping health policies and conducting research that supports the “Healthy China” initiative, contributing to the country’s efforts to improve the health and well-being of its citizens.-Fineline Info & Tech
